When are topical calcineurin inhibitors recommended for cutaneous lupus?

Cutaneous lupus affects the skin and may cause persistent scaly, red, thickened, or discoloured patches. Some forms can scar or leave lasting changes, so diagnosis and follow-up matter. A topical calcineurin inhibitor can reduce local immune inflammation and may be selected for limited lesions or areas where a steroid-sparing approach is useful. It is not a cure for lupus and may not be enough when lesions are widespread, deeply inflamed, scarring, or accompanied by symptoms outside the skin.

Apply the prescribed layer to the identified lesions and keep it away from the eyes and broken skin unless instructed otherwise. Use broad sun protection and protective clothing because ultraviolet exposure can aggravate cutaneous lupus. Avoid self-treating new lesions with strong steroid, bleaching, or exfoliating products. Report persistent burning, swelling, blistering, crusting, or any rapid change. Keep follow-up appointments so the clinician can assess activity, scarring, and the need for treatment beyond the skin.

Arrange prompt review for painful ulcers, rapidly spreading lesions, new scarring, marked hair loss in an affected area, or eye involvement. Tell your clinician about new joint pain, fever, unusual fatigue, chest symptoms, or other symptoms beyond the skin. These changes may require broader assessment rather than a topical adjustment alone.

Ask whether your lesions are appropriate for topical treatment, how sun exposure may affect them, and what signs suggest scarring or wider lupus activity. Clarify the review schedule and what to do if a new patch appears.